Attributes | Values |
---|
rdf:type
| |
description
| - clinical trial (en)
- ensayu clínicu (ast)
- klinisch onderzoek (nl)
- клінічне випробування (uk)
- կլինիկական փորձարկում (hy)
|
rdfs:label
| - Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (en)
- Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (nl)
|
skos:prefLabel
| - Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (en)
- Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (nl)
|
name
| - Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (en)
- Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (nl)
|
title
| |
title
| - Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers (en)
|
end time
| |
end time
| |
instance of
| |
instance of
| |
start time
| |
start time
| |
country
| |
country
| |
research site
| |
research site
| |
short name
| |
short name
| |
minimum age
| |
minimum age
| |
number of participants
| |
number of participants
| |
maximum age
| |
maximum age
| |
study type
| |
study type
| |
ClinicalTrials.gov ID
| |
ClinicalTrials.gov ID
| |
clinical trial phase
| |
clinical trial phase
| |
is about
of | |